T细胞受体
医学
免疫疗法
临床试验
癌症
T细胞
肿瘤科
细胞疗法
癌症免疫疗法
癌症治疗
靶向治疗
内科学
免疫学
细胞
免疫系统
生物
遗传学
作者
Jianing Li,Yongsheng Zhang,Tong Fu,Guoli Xing,Hongbo Cai,Kaiqing Li,Yutong Xu,Ying Tong
标识
DOI:10.3389/fimmu.2024.1487782
摘要
Background: T cell receptor (TCR)-T cell therapy is an innovative form of cancer immunotherapy that genetically modifies patients' T cells to target and destroy cancer cells. However, the current status of clinical trials of TCR-T cell therapy for the treatment of cancer remains unclear. This study aimed to comprehensively analyze the registration trials related to TCR-T cell therapy for the treatment of cancer. Methods: A comprehensive search was conducted in the Trialtrove database for all clinical trials related to TCR-T cell therapy registered by August 1, 2024. Inclusion criteria focused on trials targeting TCR-T cell therapy for oncology, and excluded observational studies and incomplete data. Statistical analysis was performed on key trial characteristics, with between-group comparisons utilizing chi-square or Fisher's exact tests. Results: Analysis of 174 eligible clinical trials revealed that TCR-T cell therapy exhibits significant efficacy across various tumor types, particularly in refractory hematologic malignancies and certain solid tumors. Additionally, combining TCR-T cell therapy with other immunotherapies enhanced these anti-tumor effects. Conclusion: TCR-T cell therapy holds substantial promise for cancer treatment. Future research should focus on optimizing treatment protocols, enhancing efficacy, and minimizing prices to fully realize the potential of this therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI